Should you buy Novo Nordisk stock? 3-Minute Stock Analysis - August 2025 скачать в хорошем качестве

Should you buy Novo Nordisk stock? 3-Minute Stock Analysis - August 2025

Published first at https://www.3minutebreakdowns.com Novo Nordisk stock analysis. Ticker: $NVO Novo Nordisk makes the blockbuster weight loss drugs Ozempic and Wegovy but shares are down 66% taking the company back to levels last seen in 2021. So is this game over for Novo Nordisk or is it time to load the boat? At the latest price, Novo Nordisk now has a market value of 209.5 billion dollars. The company has 6 billion of cash on its balance sheet and 14 billion of debt so the enterprise value is just under 218 billion. Meanwhile the company has generated 44 billion of revenue over the last 12 months, 15 billion of net income and 11.5 billion of free cash flow. So the stock is now valued at just 14 times earnings and 19 times free cash flow. That looks pretty cheap, on the surface. Novo Nordisk is battling several fronts. The company’s weight loss drugs Ozempic and Wegovy are losing market share to Eli Lilly’s Mounjaro and Zepbound. Prescription data shows that doctors have been leaning towards Lily’s products due to lower side effects. ABOUT ME Joe is the original founder of 3-minute Breakdowns and editor for Overlooked Alpha, the number one newsletter for overlooked investing ideas and stock market analysis. Joe evaluates companies from a business-first perspective, searching for things that the market has got wrong and waiting for the 'fat pitch'. LINKS My website: https://www.3minutebreakdowns.com/ Koyfin charts: https://www.koyfin.com/affiliate/over... TikTok:   / overlookedalpha   X: https://x.com/OverlookedAlpha DISCLAIMER & DISCLOSURE This content is for educational and entertainment purposes only. 3-Minute Breakdowns is not a registered investment advisor and does not provide financial recommendations (only opinions). The information is being presented without consideration of the investment objectives, risk tolerance, or financial circumstances of any specific investor and might not be suitable for all investors. Past performance is not indicative of future results. All investing involves risk, including the possible loss of principal. The author reserves the right to buy and sell or change his position in a particular stock at any time. This description contains affiliate links that allow you to find the items that I personally use and recommend. Thank you for your support.